Revelation Biosciences, Inc. - Common Stock (REVB)
0.8500
-0.0300 (-3.41%)
NASDAQ · Last Trade: May 31st, 4:42 AM EDT
Detailed Quote
Previous Close
0.8800
Open
0.8802
Bid
0.8361
Ask
0.8560
Day's Range
0.8390 - 0.9000
52 Week Range
2.360 - 60.48
Volume
494,181
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
37,684
Chart
About Revelation Biosciences, Inc. - Common Stock (REVB)
Revelation Biosciences Inc is a biotechnology company focused on developing innovative therapies and diagnostics to address unmet medical needs, particularly in the areas of respiratory and immune-related diseases. The company leverages its proprietary platforms to explore novel treatments that may enhance immune response or provide protection against infectious agents, utilizing advanced research methodologies and clinical trials to validate its programs. By combining cutting-edge science with a commitment to improving patient care, Revelation Biosciences aims to deliver transformative solutions in the rapidly evolving healthcare landscape. Read More
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the closing of its previously announced public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated warrant. The warrants will have an exercise price of $1.10 per share, are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years following the initial exercise date.
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the pricing of a public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated warrant. The warrants will have an exercise price of $1.10 per share, are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years following the initial exercise date. The closing of the offering is expected to occur on or about May 29, 2025, subject to the satisfaction of customary closing conditions.
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F. Tidmarsh, MD, PhD from the Company’s Board of Directors.
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended March 31, 2025 financial results.
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced a new target indication for Gemini for the prevention of infection in severe burn patients requiring hospitalization (the GEM-PBI program). The use of Gemini for the prevention of infection in severe burn patients, as well as the prevention of infection post-surgery (the GEM-PSI program) are a part of the patent family Revelation previously licensed from Vanderbilt University.
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced Gemini priming attenuates the inflammatory response in human peripheral blood mononuclear cells (PBMCs) exposed to clinically relevant promoter molecules of inflammation. Revelation anticipates demonstrating the same protective effect in patients treated with Gemini in its Phase 1b clinical study, which will provide evidence of the potential efficacy of Gemini in the Company’s target indications.
